- Paysign's underlying growth story is still intact. The continued growth of Plasma centers in the difficult environment the past two years shows underlying strength in the Plasma market.
- With shares down 90% from the 2019 high, indiscriminate tax loss selling was likely a big part of the reason shares fell 40% from solid Q3 earnings.
- Q4 Plasma segment results may surprise to the upside and have the potential to be a record quarter.
- Pharma segment provides material upside and should also improve significantly in 2022.
For further details see:
Paysign: My Top Rebound Pick For 2022